Skip to main content
Premium Trial:

Request an Annual Quote

Castle Biosciences DecisionDx-CMSeq

Castle Biosciences has launched its DecisionDx-CMSeq test, which uses next-generation sequencing to identify somatic mutations in BRAF and NRAS, two genes linked to cutaneous melanoma. The DecisionDx-CMSeq test will provide additional information to compliment the firm's DecisionDx-Melanoma gene expression profile (GEP) test that predicts individual risk of melanoma recurrence in patients. The test can be ordered with the DecisionDx-Melanoma GEP test or as a standalone request. 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.